Effectiveness of malaria chemoprophylaxis against Plasmodium falciparum infection in UK travellers: Retrospective observational data

Travel Medicine and Infectious Disease

Volumn 7, Issue 6, 2009, Pages 329-336

  Zuckerman, Jane N ^a   Batty, Anthony J ^b   Jones, Michael E ^c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Chemoprophylaxis; Malaria; Plasmodium falciparum

Indexed keywords

ATOVAQUONE PLUS PROGUANIL; DOXYCYCLINE; MEFLOQUINE;

ARTICLE; CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG USE; ENDEMIC DISEASE; HUMAN; IMPORT DISEASE; MALARIA FALCIPARUM; NATIONAL HEALTH SERVICE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; RETROSPECTIVE STUDY; TRAVEL; UNITED KINGDOM;

ANTIMALARIALS; ATOVAQUONE; CHEMOPREVENTION; CHLOROGUANIDE; DOXYCYCLINE; FEMALE; GREAT BRITAIN; HUMANS; MALARIA, FALCIPARUM; MALE; MEFLOQUINE; PLASMODIUM FALCIPARUM; RETROSPECTIVE STUDIES; RISK FACTORS; TRAVEL; TREATMENT OUTCOME;

EID: 70450277201     PISSN: 14778939     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmaid.2009.10.002     Document Type: Article

References (40)

1. Zuckerman J.N. Preventing malaria in UK travellers. BMJ 329 (2004) 305-306
2. Zuckerman J.N. Imported malaria in the UK. BMJ 337 (2008) a135
3. Health Protection Agency. Malaria imported into the UK in 2007: implications for those advising travellers vol. 2 (2008), Health Protection Report. www.hpa.org.uk/hpr/archives/2008/news1708.htm
4. Smith A.D., Bradley D.J., Smith V., Blaze M., Behrens R.H., Chiodini P.L., et al. Imported malaria and high risk groups: observational study using UK surveillance data 1987-2006. BMJ 337 (2008) a120
5. Snow R., Guerra C., Noor A., Myint H., and Hay S. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434 (2005) 214-247
6. World Health Organization. Susceptibility of Plasmodium falciparum to antimalarial drugs. Report on Global Monitoring 1996-2004 (2005), WHO, Geneva, Switzerland pp. 35-9
7. Bradley D., and Bannister B. Guidelines for malaria prevention in travellers from the United Kingdom for 2001. Commun Dis Public Health 4 (2001) 84-101
8. Chiodini P., Hill D., Lalloo D., Lea G., Walker E., Whitty C., et al. Guidelines for malaria prevention in travellers from the United Kingdom (2007), Health Protection Agency. www.hpa.org.uk/webw/HPAweb&;HPAwebStandard/HPAweb_C/1203496943315?p=1153846674367
9. Sutherland C.J., Haustein T., Gadalla N., Armstrong M., Doherty J.F., and Chiodini P.L. Chloroquine-resistant Plasmodium falciparum infections among UK travellers returning with malaria after chloroquine prophylaxis. J Antimicrob Chemother 59 (2007) 1197-1199
10. Health Protection Agency. Antimicrobial resistance and prescribing in England, Wales and Northern Ireland, 2008 (1995). www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1216798080469
11. Health Protection Agency. Antimicrobial resistance in England, Wales and Northern Ireland (2006). www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1204100435389
12. Health Protection Agency. Trends in antimicrobial resistance in England and Wales, 2001-2003 (2005). www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947326257
13. Health Protection Agency. Trends in antimicrobial resistance in England and Wales, 2004-2005 (2006). www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1196942166920
14. Gyorkos T.W., Svenson J.E., Maclean J.D., Mohamed N., Remondin M.H., and Franco E.D. Compliance with antimalarial chemoprophylaxis and the subsequent development of malaria: a matched case-control study. Am J Trop Med Hyg 53 (1995) 511-517
15. Ohrt C., Richie T.L., Widjaja H., Shanks G.D., Fitriadi J., Fryauff D.J., et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 126 (1997) 963-972
16. Overbosch D., Schilthuis H., Bienzle U., Behrens R.H., Kain K.C., Clarke P.D., et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 33 (2001) 1015-1021
17. Pang L.W., Limsomwong N., Boudreau E.F., and Singharaj P. Doxycycline prophylaxis for falciparum malaria. Lancet 1 (1987) 1161-1164
18. Shanks G.D., Gordon D.M., Klotz F.W., Aleman G.M., Oloo A.J., Sadie D., et al. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis 27 (1998) 494-499
19. Shanks G.D., Roessler P., Edstein M.D., and Rieckmann K.H. Doxycycline for malaria prophylaxis in Australian soldiers deployed to United Nations missions in Somalia and Cambodia. Mil Med 160 9 (1995) 443-445
20. Buchanan N., and Kean W. Evidence based medicine: the median is not the message. J Rheumatol 28 (2001) 2371-2372
21. Kofoed K., and Petersen E. The efficacy of chemoprophylaxis against malaria with chloroquine plus proguanil, mefloquine, and atovaquone plus proguanil in travelers from Denmark. J Travel Med 10 (2003) 150-154
22. Office of National Statistics. Mid-2007 population estimates (Aug 21 2008), Population Estimates Unit, ONS Centre for Demography, Fareham
23. British National Formulary 56. 5.4.1 Prophylaxis against malaria (2008), BMJ Group and RPS Publishing, London. www.bnf.org/bnf/bnf/56/16019.htm?q=%22malaria%22
24. British National Formulary 56. 13.6.2 Oral preparations for acne (2008), BMJ Group and RPS Publishing, London. www.bnf.org/bnf/bnf/56/6043.htm?q=%22acne%22#_hit
25. Leonard L., and Van Landingham M. Adherence to travel health guidelines: the experience of Nigerian immigrants in Houston. Texas J Immigr Health 2001 3 (2001) 31-45
26. Morgan M., and Figueroa-Munoz J. Barriers to adherence and uptake with malaria prophylaxis by the African community in London, England: a focus group study. Ethn Health 10 (2005) 355-372
27. Pistone T., Guibert P., Gay F., Malvy D., and Ezzedine K. Malaria risk perception, knowledge and prophylaxis practices among travellers of African ethnicity living in Paris and visiting their country of origin in sub-Saharan Africa. Trans R Soc Trop Med Hyg 101 (2007) 990-995
28. Rothwell P.M. Factors that can affect the external validity of randomised controlled trials. PLoS Clinical Trials 1 (2006) e9
29. Sackett D., and Wennberg J. Choosing the best research design for each question. BMJ 315 (1997) 1636
30. Schlagenhauf P., Tschopp A., Johnson R., Nothdurft H.D., Beck B., Schwartz E., et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ 327 (2003) 1078
31. Croft A., and Garner P. Mefloquine to prevent malaria: a systematic review of trials. BMJ 315 (1997) 1412-1416
32. Badrinath P., Ejidokun O.O., Barnes N., and Ramaiah S. Change in NHS regulations may have caused increase in malaria. BMJ 316 (1998) 1746-1747
33. Clift S., and Grabowski P. Malaria prophylaxis and the media. Lancet 348 (1996) 344
34. Lariam tablets 250 mg (mefloquine hydrochloride). Summary of product characteristics (February 2008), Roche Products Limited, Welwyn Garden City, UK
35. Vibramycin capsules 50 mg (doxycycline). Summary of product characteristics (May 2008), Pfizer Limited, Kent, UK
36. Jong E.C., and Nothdurft H.D. Current drugs for anti-malarial chemoprophylaxis; a review of efficacy and safety. J Travel Med 8 Suppl. 3 (2001) S48-S56
37. Malarone tablets (atovaquone 250 mg, proguanil hydrochloride 100 mg). Summary of product characteristics (May 2008), GlaxoSmithKline, Brentford, UK
38. Malarone tablets (atovaquone 250 mg, proguanil hydrochloride 100 mg). Prescribing information (June 2008), GlaxoSmithKline, Research Triangle Park, USA
39. Freedman D.O. Clinical practice. Malaria prevention in short-term travelers. N Engl J Med 359 (2008) 603-612
40. Senn N., D'Acremont V., Landry P., and Genton B. Malaria chemoprophylaxis: what do the travelers choose, and how does pretravel consultation influence their final decision. Am J Trop Med Hyg 77 (2007) 1010-1014